Listed

TherapeuticsMD, Inc.: Form 10-Q for the period ended Jun 30, 2017

Filed with the SEC on Aug 3, 2017 and accepted by EDGAR at Aug 3, 2017, 17:28 ET.

Share

Sections

The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.

Figures reported in this filing

Standardized line items from the XBRL in this filing, for the period ended 2017-06-30. Comparative periods it repeats are left out.

Figures reported in this filing
Line itemPeriodValueXBRL concept
Revenue6 months2017-01-01 to 2017-06-30$8.2mus-gaap:SalesRevenueNet
Gross profit3 months2017-04-01 to 2017-06-30$3.6mus-gaap:GrossProfit
Gross profit6 months2017-01-01 to 2017-06-30$6.9mus-gaap:GrossProfit
Research and development3 months2017-04-01 to 2017-06-30$8.7mus-gaap:ResearchAndDevelopmentExpense
Research and development6 months2017-01-01 to 2017-06-30$16.4mus-gaap:ResearchAndDevelopmentExpense
Selling, general and administrative3 months2017-04-01 to 2017-06-30$14.6mus-gaap:SellingGeneralAndAdministrativeExpense
Selling, general and administrative6 months2017-01-01 to 2017-06-30$31.5mus-gaap:SellingGeneralAndAdministrativeExpense
Operating income3 months2017-04-01 to 2017-06-30−$19.8mus-gaap:OperatingIncomeLoss
Operating income6 months2017-01-01 to 2017-06-30−$41.1mus-gaap:OperatingIncomeLoss
Net income3 months2017-04-01 to 2017-06-30−$19.7mus-gaap:NetIncomeLoss
Net income6 months2017-01-01 to 2017-06-30−$40.8mus-gaap:NetIncomeLoss
Diluted EPS3 months2017-04-01 to 2017-06-30−$0.10us-gaap:EarningsPerShareBasicAndDiluted
Diluted EPS6 months2017-01-01 to 2017-06-30−$0.20us-gaap:EarningsPerShareBasicAndDiluted
Operating cash flow6 months2017-01-01 to 2017-06-30−$38.7mus-gaap:NetCashProvidedByUsedInOperatingActivities
Capital expenditure6 months2017-01-01 to 2017-06-30$35.8kus-gaap:PaymentsToAcquirePropertyPlantAndEquipment
Cash and equivalentsAt period end2017-06-30$96.5mus-gaap:Cash
Current assetsAt period end2017-06-30$103.5mus-gaap:AssetsCurrent
Total assetsAt period end2017-06-30$106.9mus-gaap:Assets
Current liabilitiesAt period end2017-06-30$13.3mus-gaap:LiabilitiesCurrent
Shareholders' equityAt period end2017-06-30$93.6mus-gaap:StockholdersEquity

Source: SEC EDGAR, the filing index for accession 0001387131-17-003894. Last ingested by Listed: Nov 14, 2026, 19:24 ET. Listed shows no prices and gives no investment advice.